•  
  •  
 

Subject Area

Internal Medicine

Article Type

Original Study

Abstract

Objectives To elucidate the serum level of microRNA (miRNA)-192 in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Background Early diagnosis of HCC presents a challenge owing to lack of reliable biomarkers, stressing the need for new early diagnostic tools. The identification of new high-sensitivity and high-specificity markers for HCC is essential. We aimed to identify serum miRNA-192 as a biomarker to be used in diagnosing HCV-related HCC. Patients and methods We investigated serum miRNA-192 expression in 40 patients with HCC, 40 HCV-infected patients, and 20 healthy controls. An initial screening of miRNA-192 expressions by Illumina sequencing was performed using serum samples pooled from patients with HCC, HCV-infected patients, and controls. Quantitative reverse-transcriptase PCR was used to evaluate the expression of miRNA-192. Demographic, radiological, and laboratory analyses were recorded. Results MiRNA-192 was significantly increased in HCC group in comparison with HCV and control groups, with cutoff level of 62.06. Conclusion MiRNA-192 could be used as a diagnostic biomarker for early detection of HCC in HCV-related cirrhosis, as it showed significant upregulation in patients with HCC in comparison with non-HCC patients.

Download

Share

COinS